Part:BBa_K4739001
Minihepcidin, a treatment for encouragement of erythropoiesis
Minihepcidin is a peptide drug treating β-thalassemia and polycythemia vera (PV), two disorders related to erythropoiesis (red blood cell production). β-Thalassemia is characterized by ineffective erythropoiesis, anemia, and iron overload, while PV is associated with an overproduction of erythrocytes and an increased risk of blood clots. Minihepcidins are agonists of hepcidin, a key regulator of iron homeostasis, which has been shown to prevent iron overload and induce iron-restricted erythropoiesis in certain contexts. In mouse models of β-thalassemia, minihepcidin alleviated ineffective erythropoiesis, anemia, and iron overload. Furthermore, in PV mouse models that mimic the human condition through the expression of an orthologous JAK2 mutation, minihepcidin administration reduced spleen size and normalized hematocrit levels. Thus, minihepcidins showcase therapeutic potential for managing β-thalassemia and PV by mitigating various symptomatic aspects of these disorders. In our project, we link this drug to Hcp component of T6SS to utilize T6SS to deliver this drug.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
| None |